Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita

Sancy Leachman, Robyn P. Hickerson, Peter R. Hull, Frances J D Smith, Leonard M. Milstone, E. Birgitte Lane, Sherri J. Bale, Dennis R. Roop, W. H Irwin McLean, Roger L. Kaspar

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The field of science and medicine has experienced a flood of data and technology associated with the human genome project. Over 10,000 human diseases have been genetically defined, but little progress has been made with respect to the clinical application of this knowledge. A notable exception to this exists for pachyonychia congenita (PC), a rare, dominant-negative keratin disorder. The establishment of a non-profit organization, PC Project, has led to an unprecedented coalescence of patients, scientists, and physicians with a unified vision of developing novel therapeutics for PC. Utilizing the technological by-products of the human genome project, such as RNA interference (RNAi) and quantitative RT-PCR (qRT-PCR), physicians and scientists have collaborated to create a candidate siRNA therapeutic that selectively inhibits a mutant allele of KRT6A, the most commonly affected PC keratin. In vitro investigation of this siRNA demonstrates potent inhibition of the mutant allele and reversal of the cellular aggregation phenotype. In parallel, an allele-specific quantitative real-time RT-PCR assay has been developed and validated on patient callus samples in preparation for clinical trials. If clinical efficacy is ultimately demonstrated, this "first-in-skin" siRNA may herald a paradigm shift in the treatment of dominant-negative genetic disorders.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalJournal of Dermatological Science
Volume51
Issue number3
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Pachyonychia Congenita
Inborn Genetic Diseases
Small Interfering RNA
Skin
Keratins
Human Genome Project
Alleles
Genes
Nonprofit Organizations
Coalescence
Physicians
Medicine
Byproducts
Assays
Bony Callus
Therapeutics
Agglomeration
RNA Interference
RNA
Real-Time Polymerase Chain Reaction

Keywords

  • Gene therapy
  • Genodermatoses
  • Keratin
  • Pachyonychia congenita
  • RNAi
  • siRNA

ASJC Scopus subject areas

  • Dermatology

Cite this

Leachman, S., Hickerson, R. P., Hull, P. R., Smith, F. J. D., Milstone, L. M., Lane, E. B., ... Kaspar, R. L. (2008). Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. Journal of Dermatological Science, 51(3), 151-157. https://doi.org/10.1016/j.jdermsci.2008.04.003

Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. / Leachman, Sancy; Hickerson, Robyn P.; Hull, Peter R.; Smith, Frances J D; Milstone, Leonard M.; Lane, E. Birgitte; Bale, Sherri J.; Roop, Dennis R.; McLean, W. H Irwin; Kaspar, Roger L.

In: Journal of Dermatological Science, Vol. 51, No. 3, 09.2008, p. 151-157.

Research output: Contribution to journalArticle

Leachman, S, Hickerson, RP, Hull, PR, Smith, FJD, Milstone, LM, Lane, EB, Bale, SJ, Roop, DR, McLean, WHI & Kaspar, RL 2008, 'Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita', Journal of Dermatological Science, vol. 51, no. 3, pp. 151-157. https://doi.org/10.1016/j.jdermsci.2008.04.003
Leachman, Sancy ; Hickerson, Robyn P. ; Hull, Peter R. ; Smith, Frances J D ; Milstone, Leonard M. ; Lane, E. Birgitte ; Bale, Sherri J. ; Roop, Dennis R. ; McLean, W. H Irwin ; Kaspar, Roger L. / Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. In: Journal of Dermatological Science. 2008 ; Vol. 51, No. 3. pp. 151-157.
@article{b817b1cf0c3d4022b7c55d91c9ffa58c,
title = "Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita",
abstract = "The field of science and medicine has experienced a flood of data and technology associated with the human genome project. Over 10,000 human diseases have been genetically defined, but little progress has been made with respect to the clinical application of this knowledge. A notable exception to this exists for pachyonychia congenita (PC), a rare, dominant-negative keratin disorder. The establishment of a non-profit organization, PC Project, has led to an unprecedented coalescence of patients, scientists, and physicians with a unified vision of developing novel therapeutics for PC. Utilizing the technological by-products of the human genome project, such as RNA interference (RNAi) and quantitative RT-PCR (qRT-PCR), physicians and scientists have collaborated to create a candidate siRNA therapeutic that selectively inhibits a mutant allele of KRT6A, the most commonly affected PC keratin. In vitro investigation of this siRNA demonstrates potent inhibition of the mutant allele and reversal of the cellular aggregation phenotype. In parallel, an allele-specific quantitative real-time RT-PCR assay has been developed and validated on patient callus samples in preparation for clinical trials. If clinical efficacy is ultimately demonstrated, this {"}first-in-skin{"} siRNA may herald a paradigm shift in the treatment of dominant-negative genetic disorders.",
keywords = "Gene therapy, Genodermatoses, Keratin, Pachyonychia congenita, RNAi, siRNA",
author = "Sancy Leachman and Hickerson, {Robyn P.} and Hull, {Peter R.} and Smith, {Frances J D} and Milstone, {Leonard M.} and Lane, {E. Birgitte} and Bale, {Sherri J.} and Roop, {Dennis R.} and McLean, {W. H Irwin} and Kaspar, {Roger L.}",
year = "2008",
month = "9",
doi = "10.1016/j.jdermsci.2008.04.003",
language = "English (US)",
volume = "51",
pages = "151--157",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita

AU - Leachman, Sancy

AU - Hickerson, Robyn P.

AU - Hull, Peter R.

AU - Smith, Frances J D

AU - Milstone, Leonard M.

AU - Lane, E. Birgitte

AU - Bale, Sherri J.

AU - Roop, Dennis R.

AU - McLean, W. H Irwin

AU - Kaspar, Roger L.

PY - 2008/9

Y1 - 2008/9

N2 - The field of science and medicine has experienced a flood of data and technology associated with the human genome project. Over 10,000 human diseases have been genetically defined, but little progress has been made with respect to the clinical application of this knowledge. A notable exception to this exists for pachyonychia congenita (PC), a rare, dominant-negative keratin disorder. The establishment of a non-profit organization, PC Project, has led to an unprecedented coalescence of patients, scientists, and physicians with a unified vision of developing novel therapeutics for PC. Utilizing the technological by-products of the human genome project, such as RNA interference (RNAi) and quantitative RT-PCR (qRT-PCR), physicians and scientists have collaborated to create a candidate siRNA therapeutic that selectively inhibits a mutant allele of KRT6A, the most commonly affected PC keratin. In vitro investigation of this siRNA demonstrates potent inhibition of the mutant allele and reversal of the cellular aggregation phenotype. In parallel, an allele-specific quantitative real-time RT-PCR assay has been developed and validated on patient callus samples in preparation for clinical trials. If clinical efficacy is ultimately demonstrated, this "first-in-skin" siRNA may herald a paradigm shift in the treatment of dominant-negative genetic disorders.

AB - The field of science and medicine has experienced a flood of data and technology associated with the human genome project. Over 10,000 human diseases have been genetically defined, but little progress has been made with respect to the clinical application of this knowledge. A notable exception to this exists for pachyonychia congenita (PC), a rare, dominant-negative keratin disorder. The establishment of a non-profit organization, PC Project, has led to an unprecedented coalescence of patients, scientists, and physicians with a unified vision of developing novel therapeutics for PC. Utilizing the technological by-products of the human genome project, such as RNA interference (RNAi) and quantitative RT-PCR (qRT-PCR), physicians and scientists have collaborated to create a candidate siRNA therapeutic that selectively inhibits a mutant allele of KRT6A, the most commonly affected PC keratin. In vitro investigation of this siRNA demonstrates potent inhibition of the mutant allele and reversal of the cellular aggregation phenotype. In parallel, an allele-specific quantitative real-time RT-PCR assay has been developed and validated on patient callus samples in preparation for clinical trials. If clinical efficacy is ultimately demonstrated, this "first-in-skin" siRNA may herald a paradigm shift in the treatment of dominant-negative genetic disorders.

KW - Gene therapy

KW - Genodermatoses

KW - Keratin

KW - Pachyonychia congenita

KW - RNAi

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=48049103228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049103228&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2008.04.003

DO - 10.1016/j.jdermsci.2008.04.003

M3 - Article

C2 - 18495438

AN - SCOPUS:48049103228

VL - 51

SP - 151

EP - 157

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 3

ER -